Welcome to our dedicated page for Ptc Therapeutics news (Ticker: PTCT), a resource for investors and traders seeking the latest updates and insights on Ptc Therapeutics stock.
PTC Therapeutics (PTCT) provides critical updates through this centralized news resource for investors and industry stakeholders. Track official announcements spanning clinical trial progress, regulatory milestones, and strategic partnerships in rare disease therapeutics.
Access timely updates on PTCT's small molecule developments, gene therapy advancements, and financial disclosures. Our curated feed ensures comprehensive coverage of material events including FDA submissions, research collaborations, and commercialization efforts.
This repository features verified press releases covering:
• Clinical trial results for neuromuscular and oncology programs
• Regulatory filings and orphan drug designations
• Strategic alliances with research institutions
• Financial performance and earnings communications
Bookmark this page for direct access to PTCT's evolving developments in post-transcriptional control therapeutics. Monitor breakthrough innovations addressing Duchenne muscular dystrophy, genetic disorders, and underserved patient populations.
PTC Therapeutics (NASDAQ: PTCT) reported Q3 2025 total revenue of $211.0M and positive net income of $15.9M. The company initiated the global launch of Sephience (sepiapterin), recording $19.6M in Sephience revenue, 521 US patient start forms from 141 prescribers, and 341 patients on commercial therapy worldwide as of September 30, 2025.
Third-quarter product revenue was $131.0M with royalty and collaboration revenue of $80.1M (including $70.8M royalty from Evrysdi). Cash, cash equivalents and marketable securities were $1.688B at quarter end. PTC narrowed full-year 2025 revenue guidance to $750–$800M and projects GAAP R&D and SG&A of $805–$835M (non-GAAP $730–$760M).
PTC Therapeutics (NASDAQ: PTCT) announced executive presentations at three investor conferences: UBS Global Healthcare Conference on Nov 11, 2025 at 3:30 p.m. EST, Jefferies Global Healthcare Conference on Nov 18, 2025 at 8:00 a.m. GMT / 3:00 a.m. EST, and Citi 2025 Global Healthcare Conference on Dec 4, 2025 at 10:30 a.m. EST.
All presentations will be webcast live and archived for 30 days on PTC's Investor Events and Presentations page. Users are advised to connect to the webcast several minutes early to ensure a timely connection.
PTC Therapeutics (NASDAQ: PTCT) announced inducement equity grants approved Oct. 23, 2025 for two new employees under Nasdaq Listing Rule 5635(c)(4).
The company granted non-statutory stock options to purchase an aggregate of 2,000 shares and 1,990 restricted stock units (RSUs). Options have an exercise price of $66.80 (closing price on Oct. 23, 2025), a 10-year term, and vest over four years: 25% at the first anniversary then 6.25% quarterly thereafter. RSUs vest over four years with 25% vesting on each annual anniversary. Grants were approved by the Compensation Committee and made as inducements to accept employment.
PTC Therapeutics (NASDAQ: PTCT) will host a webcast conference call to report third quarter 2025 financial results and provide a business outlook on Tuesday, November 4, 2025 at 4:30 p.m. ET.
Participants can register for phone access to receive dial-in details and are advised to dial in 15 minutes early. The live webcast will be available in the Investors section at https://ir.ptcbio.com/events-presentations. A replay will be posted about two hours after the call and will remain archived on the company website for 30 days.
PTC Therapeutics (NASDAQ: PTCT) announced the approval of equity compensation awards for 48 new employees. The company granted 19,475 non-statutory stock options at an exercise price of $58.99 per share and 39,060 restricted stock units (RSUs).
The stock options have a 10-year term with a 4-year vesting schedule: 25% vesting after one year and 6.25% quarterly thereafter. The RSUs also vest over four years, with 25% vesting annually. These inducement grants were approved by PTC's Compensation Committee under Nasdaq Listing Rule 5635(c)(4) as part of new hire compensation packages.
PTC Therapeutics (NASDAQ: PTCT) has announced its participation in three major healthcare investor conferences in September 2025. The company will present at the Cantor Global Healthcare Conference on September 3 at 8:35 a.m. ET, the Wells Fargo Healthcare Conference on September 4 at 11:00 a.m. ET, and the Morgan Stanley Global Healthcare Conference on September 8 at 9:15 a.m. ET.
All presentations will be available via webcast on PTC's investor relations website and will remain accessible for 30 days after each event.
PTC Therapeutics (NASDAQ: PTCT) has received a Complete Response Letter (CRL) from the FDA regarding its New Drug Application (NDA) for vatiquinone, intended to treat Friedreich's ataxia in children and adults.
The FDA determined that substantial evidence of efficacy was not demonstrated for vatiquinone and stated that an additional adequate and well-controlled study would be required to support NDA resubmission. CEO Matthew B. Klein expressed disappointment with the FDA's decision and indicated the company plans to meet with the FDA to address the issues raised in the CRL.
PTC Therapeutics (NASDAQ:PTCT) reported Q2 2025 financial results and corporate updates. The quarter was marked by the European and FDA approval of Sephience™ for PKU treatment with broad labeling. Total revenue reached $178.9 million, including $96 million from the DMD franchise. The company reported a net loss of $64.8 million, improved from $99.2 million in Q2 2024.
Key highlights include cash position of $1.99 billion, positive Phase 2 PIVOT-HD study results for votoplam in Huntington's Disease, and ongoing NDA reviews for vatiquinone and Translarna. PTC updated its full-year 2025 revenue guidance to $650-800 million.
The company entered an agreement to purchase Sephience's annual sales obligation for $225 million upfront plus future milestone payments.PTC Therapeutics (NASDAQ: PTCT) has received FDA approval for SEPHIENCE™ (sepiapterin), a treatment for phenylketonuria (PKU) in patients aged 1 month and older. The approval covers broad labeling for hyperphenylalaninemia (HPA) in sepiapterin-responsive PKU patients.
The approval is supported by significant efficacy and safety data from the Phase 3 APHENITY trial and its long-term extension study. SEPHIENCE has already received European Commission marketing authorization, with approval applications under review in Japan and Brazil.
The company aims to position SEPHIENCE as the future standard of care for PKU patients, with their experienced teams ready to launch the therapy in the United States.
PTC Therapeutics (NASDAQ: PTCT) has scheduled its second quarter 2025 financial results conference call for Thursday, August 7, at 4:30 p.m. ET. The presentation will include financial results and a business update. Participants are advised to register in advance and dial in 15 minutes before the call to avoid delays.
The webcast will be accessible through PTC's investor relations website, with a replay available for 30 days after the presentation.
FAQ
What is the current stock price of Ptc Therapeutics (PTCT)?
What is the market cap of Ptc Therapeutics (PTCT)?
